Supplementary Material for: Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study

Zhiwei Wang, E. Wang, Wenyu Bai, Dongdong Xia, Rong Ding, Jiaqi Li, Qun Wang, Lei Liu, Jian-Rong Sun, Wei Mu, Huihui Zhao, Xiaorong Pan, Guoliang Shao, Xiaofeng Zhu, Guobing Yin, Hongyan Shi, Junxin Wu, Z Lin, Sirui Yang, Jing Liu, Wei Wang, Yi Lv, Hong Chen, Kangpeng Li, Xulong Yuan, T.q. Yu, Jing Yuan, Xiaogang Li, Jing Niu, Zhanxin Yin, Jielai Xia, Fan Dong, Guohong HanFigshare 2020 · DOI · OpenAlex

Abstract

<b><i>Introduction:</i></b> The benefits of combining transarterial chemoembolization (TACE) and sorafenib (TACE-S) over TACE alone for treatment of unresectable hepatocellular carcinoma (HCC) remain controversial. Yet, such populations are heterogeneous in terms of baseline characteristics. <b><i>Objective:</i></b> To investigate the predictors of survival benefits from added sorafenib and identify the potential candidates for TACE-S. <b><i>Methods:</i></b> This multicenter observational study was conducted in 17 Chinese tertiary hospitals for patients with unresectable, liver-confined HCC. Eligible patients with performance status score of ≤1 and Child-Pugh score of ≤7 were treated with TACE or TACE-S. Interactions between treatment and baseline variables were evaluated to find indicators for survival benefits, based on which the patients were stratified. Multivariate models adjusted for baseline characteristics or propensity score were used to compare overall survival (OS) and time to tumor progression (TTP). <b><i>Results:</i></b> From January 2009 to December 2015, 1,719 consecutive patients received TACE (<i>n</i> = 1,406) or TACE-S (<i>n</i> = 313). Although TACE-S compared with TACE improved TTP (adjusted hazard ratio [HR] 0.75, <i>p</i> = 0.008), no difference in OS was observed (adjusted HR 0.87, <i>p</i> = 0.090). Nevertheless, the tumor burden (sum of maximum diameter of largest tumor [cm] and tumor number) and albumin-bilirubin (ALBI) score independently predicted the survival benefits from added sorafenib (interaction <i>p</i>&lt; 0.001). For patients with either moderate tumor burden (7–13) or low ALBI score (no more than –2.8) defined as candidates, TACE-S prolonged OS (adjusted HR 0.73, <i>p</i> = 0.003) and TTP (adjusted HR 0.72, <i>p</i> = 0.014) compared to TACE alone, whereas its superiority disappeared in non-candidates. <b><i>Conclusions:</i></b> Not all unresectable HCC patients but those with moderate tumor burden or low ALBI score achieve survival benefits from TACE-S compared with TACE alone. Future randomized controlled trials focusing on the subset are warranted.
BibTeX
@inproceedings{wang2020supplementary,
  author = {Zhiwei Wang and E. Wang and Wenyu Bai and Dongdong Xia and Rong Ding and Jiaqi Li and Qun Wang and Lei Liu and Jian-Rong Sun and Wei Mu and Huihui Zhao and Xiaorong Pan and Guoliang Shao and Xiaofeng Zhu and Guobing Yin and Hongyan Shi and Junxin Wu and Z Lin and Sirui Yang and Jing Liu and Wei Wang and Yi Lv and Hong Chen and Kangpeng Li and Xulong Yuan and T.Q. Yu and Jing Yuan and Xiaogang Li and Jing Niu and Zhanxin Yin and Jielai Xia and Fan Dong and Guohong Han},
  title = {{Supplementary Material for: Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study}},
  booktitle = {Figshare},
  year = {2020},
  doi = {10.6084/m9.figshare.11871534},
}

Loading related content...

Figure